Sagimet Biosciences Inc (NASDAQ:SGMT) has a beta value of 2.43 and has seen 0.45 million shares traded in the recent trading session. The company, currently valued at $93.87M, closed the recent trade at $3.06 per share which meant it lost -$0.2 on the day or -6.13% during that session. The SGMT stock price is -141.18% off its 52-week high price of $7.38 and 21.9% above the 52-week low of $2.39. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.31 million shares traded. The 3-month trading volume is 845.62K shares.
The consensus among analysts is that Sagimet Biosciences Inc (SGMT) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Sporting -6.13% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the SGMT stock price touched $3.06 or saw a rise of 25.0%. Year-to-date, Sagimet Biosciences Inc shares have moved -32.00%, while the 5-day performance has seen it change -24.07%. Over the past 30 days, the shares of Sagimet Biosciences Inc (NASDAQ:SGMT) have changed -11.30%. Short interest in the company has seen 4.19 million shares shorted with days to cover at 8.71.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 49.0% from the levels at last check today. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -96.08% off the targeted high while a plunge would see the stock gain -96.08% from the levels at last check today.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
The company’s shares have gained 8.51% over the past 6 months. If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -16.85% over the past 5 years.
SGMT Dividends
Sagimet Biosciences Inc is expected to release its next earnings report on 2025-Mar-11 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Insiders own 14.65% of the company shares, while shares held by institutions stand at 57.75% with a share float percentage of 67.67%. Investors are also buoyed by the number of investors in a company, with Sagimet Biosciences Inc having a total of 80.0 institutions that hold shares in the company. The top two institutional holders are POINT72 ASSET MANAGEMENT, L.P. with over 2.37 million shares worth more than $8.09 million. As of 2024-06-30, POINT72 ASSET MANAGEMENT, L.P. held 7.414% of shares outstanding.
The other major institutional holder is NEA MANAGEMENT COMPANY, LLC, with the holding of over 2.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.84 million and represent 6.2677% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust. As of Dec 31, 2024, the former fund manager holds about 2.49% shares in the company for having 763.99 shares of worth $2.31 million while later fund manager owns 408.12 shares of worth $1.24 million as of Dec 31, 2024, which makes it owner of about 1.33% of company’s outstanding stock.
